# Chengdu Anjian Likang Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chengdu-anjian-likang-biotechnology-co

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Latest round: Series A (Jan 26, 2026)
- Investors on record: 2

## About

Based in Chengdu, China and founded in 2025, Chengdu Anjian Likang Biotechnology Co., Ltd. provides drug discovery solutions for the healthcare industry. The company was established to focus on the research and innovation of ENDOD1 small molecule inhibitors. In January 2026, the company closed a series A funding round from CDHT Hi-Tech Venture and Orinno Capital.

The company works with medical researchers to provide small molecule inhibitors" and develops "ENDOi," a targeted drug that has shown progression-free, partial, or complete response results in treating high grade serous ovarian cancer and advanced pancreatic cancer.

The company’s revenue is generated by the research and development of biopharmaceutical products.

The company plans to accelerate the research and development of its ENDOD1 small molecule inhibitors, specifically aiming to submit IND applications in China and the United States in 2026 and to expand its market layout.

## Funding rounds

- Series A, Jan 26, 2026 — CDHT Hi-Tech Venture, Orinno Capital

## Investors

- CDHT Hi-Tech Venture (https://capitalatlas.ai/funds/cdht-hi-tech-venture) — Series A
- Orinno Capital (https://capitalatlas.ai/funds/orinno-capital) — Series A